AbbVie Financial News

30.12 / 15:59

markets COST UPS Provident wellness AbbVie Credit spreads haven’t looked this good since the 2000s. Can they get better?

Subscribe to enjoy similar stories. Companies took advantage of favorable financing conditions this year to issue debt at levels not seen since the pandemic, adding cash to the balance sheet to pay for future refinancing needs and other projects. Underpinning the surge in debt issuance: credit spreads, a metric that finance chiefs watch when deciding when to pull the trigger on a bond sale.

25.12 / 00:15

UPS Healthcare AbbVie hospital travelers patient Pharmaceuticals Mint Primer: Why are docs in the dock over a ‘work trip’?

Subscribe to enjoy similar stories. In May 2024, the DoP received an anonymous complaint alleging AbbVie Healthcare India flew 30 doctors—experts in Botox and Juvederm—to Paris and Monaco. It said the firm treated the doctors to “extravagant pleasure trips under the guise of conferences", that AbbVie purportedly flew doctors to a medical conference held in these locations.

23.12 / 18:25

markets Action Software Healthcare AbbVie travelers Pharmaceuticals AbbVie Healthcare under government lens for 'violations'

department of pharmaceuticals (DoP) has reprimanded AbbVie Healthcare India for unethical marketing practices after a top panel found the company violated provisions of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) by sponsoring foreign vacations to Monaco and Paris for 30 doctors.

12.03 / 02:27

markets Provident Coca-Cola wellness Trade AbbVie performer market volatility 3 Dividend Kings to Navigate Market Volatility With Steady Cashflow, Growth

In a world of fast-changing technology and shifts in renewable energies, dividend kings might not grab the spotlight, but their consistency makes them valuable assets for many investors. As the market faces uncertainty, investors seek stability, and dividend kings provide a reliable foundation.

21.02 / 23:49

Reuters CEO AbbVie ImmunoGen reports AbbVie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports

(Reuters) — AbbVie (NYSE:ABBV) is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen (NASDAQ:IMGN) and Cerevel Therapeutics, Bloomberg News reported on Wednesday, citing people with knowledge of the matter.

10.01 / 17:43

markets UPS JPMorgan Healthcare Trade AbbVie AbbVie expects Botox market share to stay strong despite newer rivals

(Reuters) -AbbVie expects its share of Botox in the aesthetics market to remain strong in the fourth quarter, despite recent launches of newer, longer-acting products by rivals, a company executive said on Wednesday.

09.01 / 19:36

markets UPS Waves J&J AbbVie innovations rights Investors see 6,700 Percent Gains as J&J Snaps Up Ambrx in Biotech Deal

Quiver Quantitative — The biotechnology sector, known for its high-risk, high-reward investment landscape, has once again proven its potential for delivering staggering returns. The recent acquisition of Ambrx Biopharma by Johnson & Johnson (JNJ) serves as a prime example. J&J's offer to purchase Ambrx at $28 per share represents a significant premium over its previous closing price, effectively valuing the company at an impressive $2 billion. This deal is particularly noteworthy for Ambrx's shareholders, who saw the stock languishing at a mere 41 cents per share in December 2022, a low that had put the company at risk of delisting.

05.01 / 16:41

UPS Provident Waves JPMorgan Healthcare AbbVie Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

By David Carnevali

08.12 / 02:37

Reuters Google JPMorgan Gemini AbbVie band reports 5 things that changed for the stock market over night - Gifty Nifty to Japan Q3 GDP data

Bank of India's (RBI) monetary policies are currently the centre of attention for the market. The Monetary Policy Committee (MPC) of the Reserve Bank of India is currently holding a three-day policy meeting. The meeting ends on today.

07.12 / 14:35

Reuters SEC Action AbbVie Inside reports Cerevel options trading surge before AbbVie deal news raises eyebrows

By Saqib Iqbal Ahmed

06.12 / 22:47

Waves AbbVie surges After-hours movers: Cerevel surges on takeover, Chewy falls following results

After-Hours Stock Movers:

06.12 / 22:34

CEO AbbVie patient medicines AbbVie enters agreement to acquire Cerevel Therapeutics

AbbVie Inc . (NYSE:ABBV) announced Wednesday, alongside Cerevel Therapeutics (CERE), that the two have entered into a definitive agreement for AbbVie to acquire Cerevel, as well as its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates.

01.12 / 00:42

AbbVie ImmunoGen Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio

AbbVie is spending more than $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales

30.11 / 14:17

Merit Strategy AbbVie ImmunoGen reports Immunogen shares surge on news of takeover by AbbVie

AbbVie (NYSE:ABBV) announced Thursday that it will acquire Immunogen (IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share.

30.11 / 13:15

AbbVie ImmunoGen testing patient AbbVie signs $10.1 billion deal to buy cancer drugmaker ImmunoGen

(Reuters) -AbbVie said on Thursday it will buy drugmaker ImmunoGen (NASDAQ:IMGN) for $10.1 billion, adding a promising drug for ovarian cancer to its portfolio of oncology treatments.

09.11 / 21:39

Target Progressive CEO Remark Tesla Gilead AbbVie play Stock Market Today: Dow ends lower after Powell signals rate hikes remain in play

Investing.com -- The Dow closed lower Thursday, as Federal Reserve chairman Jerome Powell dealt a blow to bets on sooner rather later rate cuts after signaling that the Fed isn't ready to close the curtain on rate hikes.

07.11 / 17:51

Twitter Booking Action AbbVie patient US FTC disputes listing for more than 100 patents in FDA Orange Book

WASHINGTON (Reuters) — The U.S. Federal Trade Commission (FTC) on Tuesday said it sent notice letters to Abbvie, AstraZeneca (NASDAQ:AZN), Teva and other drugmakers and medical device companies disputing the accuracy or relevance of more than 100 patents listed in the U.S. Food and Drug Administration's Orange Book.

30.10 / 16:24

Target Booking JPMorgan PTC AbbVie performer reports analyst Abbvie selloff overdone, says Barclays: 5 big analyst picks

Investing.com — Here is your Pro Recap of the biggest analyst picks you may have missed today: upgrades at PTC, Abbvie, East West Bancorp , Eastman Chemical, and L3Harris Technologies.

27.10 / 18:21

Morningstar Amgen AbbVie reports patient AbbVie takes $2.1 billion charge on cancer drug ahead of US price negotiation

By Leroy Leo and Christy Santhosh

29.08 / 10:43

COST Merck Pfizer Patrick AbbVie cover US to name first 10 drugs for Medicare price negotiation

By Patrick Wingrove

28.07 / 14:05

CEO Intel AbbVie country L'Oreal What are global companies saying about China's economy?

(Reuters) — Major global firms ranging from banks to chipmakers are taking a largely cautious stance on their China business amid a frail recovery at the world's second-largest economy from a pandemic slowdown.

frequently asked questions about AbbVie

What is AbbVie and why is it relevant?

AbbVie is a significant category that draws public attention. On our site, we regularly publish updates related to this subject.

Where can I find the latest updates on AbbVie?

All recent news about AbbVie can be found in the special selection. We publish information in a timely manner.

How can I verify the accuracy of information on AbbVie?

We rely on trusted sources to ensure that the information about AbbVie is well-supported and informative for our readers.